Back to results
Bibliographic record · Consultation and access
Artículo

Glutamate and modeling of schizophrenia symptoms: Review of our Findings: 1990-2014

Gargiulo, Pascual Angel et al · Elsevier · 2014

Open-access full text
Quick overview. Review the resource’s basic details, then access the content using the main button. This page shows only the information needed to identify, cite, and open the work.

Resource access

Open the content from the main option or choose another available source.

CONICET Digital CONICET Digital OAI-PMH
Entrar por CONICET Digital
Main access

Open-access full text

Texto completo identificado como acceso abierto.
Open text

Summary

Descripción general del contenido del recurso.

In the early 90s, we studied the role of perception disturbances in schizophrenia in our first clinical approaches, using the Bender test in schizophrenic patients. Results were clear, showing a shape discrimination failure. Following this initial results, we reproduced nuclear symptoms of schizophrenia in animal models, showing that perceptual disturbances, acquisition disturbances, decrease in affective levels and working memory disturbances can be induced by specific N-methyl-D-aspartic acid (NMDA) glutamatergic blockade within the nucleus accumbens septi (NAS). We studied also another glutamatergic and dopaminergic drugs, finding that a decrease in glutamatergic transmission within NAS led to cognitive disturbances and affective flattening. An increase in glutamatergic transmission fully enhances cognition in the tasks used. Dopaminergic D-2 antagonists partially improved cognition. Our results link the proposed corticostriatal dysfunction with the thalamocortical disturbances underlying perceptual problems, but also influencing affective levels and cognitive variables. According to our translational findings, core schizophrenia symptoms may be translationally reproduced antagonizing NMDA receptors within NAS, and improved blocking the glutamate auto-receptor. Dopaminergic transmission appears to have a role in therapeutic but not in the early pathophysiology of schizophrenia. Fil: Gargiulo, Pascual Angel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina. Universidad Nacional de Cuyo; Argentina Fil: Landa, Adriana Inés. Universidad Nacional de Cuyo. Facultad de Ciencias Médicas; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Mendoza. Instituto de Medicina y Biología Experimental de Cuyo; Argentina

How to cite

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

Gargiulo, P. A. E. A. (2014). Glutamate and modeling of schizophrenia symptoms: Review of our Findings: 1990-2014. http://hdl.handle.net/11336/27963

MLA

Gargiulo, Pascual Angel et al. "Glutamate and modeling of schizophrenia symptoms: Review of our Findings: 1990-2014." 2014. http://hdl.handle.net/11336/27963.

Chicago

Gargiulo, Pascual Angel et al. 2014. "Glutamate and modeling of schizophrenia symptoms: Review of our Findings: 1990-2014.". http://hdl.handle.net/11336/27963.

Harvard

Gargiulo, P. A. E. A. 2014, Glutamate and modeling of schizophrenia symptoms: Review of our Findings: 1990-2014, Elsevier, available at: http://hdl.handle.net/11336/27963 [Accessed 8 Aug. 2026].

Share and print

Save the record, copy its permanent link, or print it as a PDF.

Export reference

You can export the record in common formats for use in a reference manager.

Resource details

Bibliographic information to help confirm that this is the correct material.

Title
Glutamate and modeling of schizophrenia symptoms: Review of our Findings: 1990-2014
Author / contributors
Gargiulo, Pascual Angel et al
Publisher
Elsevier
Publication year
2014
ISSN
1990-2014
ISSN
1990-2014
Language
English

Subjects

Explore related resources through these subjects.

Copied